3247 related articles for article (PubMed ID: 23816960)
21. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
[TBL] [Abstract][Full Text] [Related]
22. Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study.
Kawano Y; Ohyanagi F; Yanagitani N; Kudo K; Horiike A; Tanimoto A; Nishizawa H; Ichikawa A; Sakatani T; Nakatomi K; Hagiwara S; Ninomiya H; Motoi N; Ishikawa Y; Horai T; Nishio M
Anticancer Res; 2013 Aug; 33(8):3327-33. PubMed ID: 23898099
[TBL] [Abstract][Full Text] [Related]
23. A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.
Chu QS; Sangha R; Hotte SJ; Sergenson G; Schnell D; Chand VK; Hirte HW
Invest New Drugs; 2014 Dec; 32(6):1226-35. PubMed ID: 25037863
[TBL] [Abstract][Full Text] [Related]
24. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
Yang JC; Shih JY; Su WC; Hsia TC; Tsai CM; Ou SH; Yu CJ; Chang GC; Ho CL; Sequist LV; Dudek AZ; Shahidi M; Cong XJ; Lorence RM; Yang PC; Miller VA
Lancet Oncol; 2012 May; 13(5):539-48. PubMed ID: 22452895
[TBL] [Abstract][Full Text] [Related]
25. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.
Yang JC; Sequist LV; Zhou C; Schuler M; Geater SL; Mok T; Hu CP; Yamamoto N; Feng J; O'Byrne K; Lu S; Hirsh V; Huang Y; Sebastian M; Okamoto I; Dickgreber N; Shah R; Märten A; Massey D; Wind S; Wu YL
Ann Oncol; 2016 Nov; 27(11):2103-2110. PubMed ID: 27601237
[TBL] [Abstract][Full Text] [Related]
26. Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment.
Shi SB; Hu RH; Qi JL; Tang XY; Tian J; Li R; Chang CX
Med Oncol; 2013; 30(2):550. PubMed ID: 23576138
[TBL] [Abstract][Full Text] [Related]
27. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
Yang CJ; Tsai MJ; Hung JY; Lee MH; Tsai YM; Tsai YC; Hsu JF; Liu TC; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 Dec; 18(1):82. PubMed ID: 29237484
[TBL] [Abstract][Full Text] [Related]
28. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
Tan PT; Aziz MIA; Pearce F; Lim WT; Wu DB; Ng K
BMC Cancer; 2018 Mar; 18(1):352. PubMed ID: 29587666
[TBL] [Abstract][Full Text] [Related]
29. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
30. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
Miller VA; Hirsh V; Cadranel J; Chen YM; Park K; Kim SW; Zhou C; Su WC; Wang M; Sun Y; Heo DS; Crino L; Tan EH; Chao TY; Shahidi M; Cong XJ; Lorence RM; Yang JC
Lancet Oncol; 2012 May; 13(5):528-38. PubMed ID: 22452896
[TBL] [Abstract][Full Text] [Related]
31. [Effects of EGFR-TKIs on sequential pemetrexed
for advanced pulmonary adenocarcinoma].
Wang X; Liu Y; Gao Z; Jiang Y; Han B; Jiang L
Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):294-8. PubMed ID: 22613336
[TBL] [Abstract][Full Text] [Related]
32. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Lee CK; Brown C; Gralla RJ; Hirsh V; Thongprasert S; Tsai CM; Tan EH; Ho JC; Chu da T; Zaatar A; Osorio Sanchez JA; Vu VV; Au JS; Inoue A; Lee SM; Gebski V; Yang JC
J Natl Cancer Inst; 2013 May; 105(9):595-605. PubMed ID: 23594426
[TBL] [Abstract][Full Text] [Related]
33. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial.
Han B; Jin B; Chu T; Niu Y; Dong Y; Xu J; Gu A; Zhong H; Wang H; Zhang X; Shi C; Zhang Y; Zhang W; Lou Y; Zhu L; Pei J
Int J Cancer; 2017 Sep; 141(6):1249-1256. PubMed ID: 28560853
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma].
He P; Wang Y; Yang S; Yu S; Wang Z; Li J; Wang B; Hao X; Wang H; Hu X; Zhang X; Shi Y
Zhongguo Fei Ai Za Zhi; 2013 Oct; 16(10):529-34. PubMed ID: 24113006
[TBL] [Abstract][Full Text] [Related]
35. Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes.
Jiang X; Yang B; Lu J; Zhan Z; Li K; Ren X
Tumour Biol; 2015 Feb; 36(2):861-9. PubMed ID: 25301443
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
37. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Paz-Ares L; Tan EH; O'Byrne K; Zhang L; Hirsh V; Boyer M; Yang JC; Mok T; Lee KH; Lu S; Shi Y; Lee DH; Laskin J; Kim DW; Laurie SA; Kölbeck K; Fan J; Dodd N; Märten A; Park K
Ann Oncol; 2017 Feb; 28(2):270-277. PubMed ID: 28426106
[TBL] [Abstract][Full Text] [Related]
38. Second-line epidermal growth factor receptor inhibitors followed by third-line pemetrexed or the reverse sequence: a retrospective analysis of 83 Chinese patients with advanced lung adenocarcinoma.
Hong T; Zhang R; Cai D; Wu X; Hua D
J Cancer Res Clin Oncol; 2012 Feb; 138(2):285-91. PubMed ID: 22116317
[TBL] [Abstract][Full Text] [Related]
39. First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial.
Boye M; Wang X; Srimuninnimit V; Kang JH; Tsai CM; Orlando M; Puri T; Kim JS; Rajan N; Yang JC
Clin Lung Cancer; 2016 Mar; 17(2):150-60. PubMed ID: 26809984
[TBL] [Abstract][Full Text] [Related]
40. Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan.
Graham J; Earnshaw S; Burslem K; Lim J
J Manag Care Spec Pharm; 2018 Jun; 24(6):544-553. PubMed ID: 29799327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
